Celebrating GILZRx: a Monash biotech success story

Associate Professor Sarah Jones and her Rheumatology Research team at the Monash University Centre for Inflammatory Diseases have received an additional AU$500,000 in funding from Brandon BioCatalyst's CUREator incubator for their biotech startup, GILZRx.

SDG9-Res3 GILZRx biotech startup

This funding, totaling AU$1M, will support the development of a new anti-inflammatory medicine aimed at providing a safer alternative to glucocorticoids, which are used by many people worldwide but have severe side effects.

This advancement could revolutionise treatment for autoimmune diseases and inflammatory disorders.

Read the full article in Monash Medicine News

Related SDGs

SDG 3 Good Health and Well-being SDG 17 Partnerships For The Goals